Policy

Bills in House, Senate Seek to Address Role of Patents in High Prescription Drug Prices

June 20th 2019

By Allison Inserro

Legislators on Capitol Hill are moving forward this month with bills that address patent issues pertaining to biosimilars.

New Questions Arise About the Need for Lengthy Biologic Exclusivity Periods

June 20th 2019

By Kelly Davio

According to the authors of a new study, while biologics are often believed to be more time consuming to develop than small-molecule drugs, development times are, in fact, similar between these 2 drug types.

Insulin Rationing Is a Global Problem, But at Its Worst in the United States

June 19th 2019

By Allison Inserro

A worldwide survey conducted by an international type 1 diabetes (T1D) advocacy non-profit found that rationing of insulin and related supplies was the greatest in the Unites States.

Advisory Council Supports Biosimilars in Call for Universal Public Drug Coverage in Canada

June 17th 2019

By Allison Inserro

A Canadian advisory council is recommending the use of biosimilars in a final report that lays out 60 recommendations for how the country can create a C$15.3 billion universal, single-payer, public system for pharmaceutical coverage.

Gary Lyman, MD, MPH: Biosimilars and Policy

June 17th 2019

Gary Lyman, MD, MPH, of the Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance, discusses policy challenges with biosimilars.

Ireland Makes a Push to Switch to Biosimilar Adalimumab and Etanercept

June 17th 2019

By The Center for Biosimilars Staff

Irish hospitals will be offered a €500 (US $561) incentive for each patient switched from brand-name Humira or Enbrel to a biosimilar option.

The Top 5 Biosimilars Articles for the Week of June 10

June 14th 2019

The Center for Biosimilars® recaps the top stories for the week of June 10, 2019.

AMA Calls for State-Level Legislation to Rein in PBMs

June 12th 2019

By The Center for Biosimilars Staff

The American Medical Association (AMA), which is holding its annual meeting this week in Chicago, Illinois, has issued a call for intensified oversight of the pharmacy benefit manager (PBM) industry.

Biosimilar Proposal for Medicare Will Depend on the Details

June 11th 2019

By Allison Inserro

“Do I think these numbers are reasonable and achievable? Potentially,” said Christina Corridon, MPH, MBA, a principal with the consulting firm ZS.

"Biomimics" Are Not Biosimilars, PANLAR Statement Warns

June 10th 2019

By Allison Inserro

A consensus statement developed by the Pan American League of Associations for Rheumatology (PANLAR) regarding biosimilars warned against the use of so-called "biomimics," or copy biologics.